Briviact FDA Approval History
FDA Approved: Yes (First approved February 19, 2016)
Brand name: Briviact
Generic name: brivaracetam
Company: UCB, Inc.
Treatment for: Epilepsy
Briviact (brivaracetam) is a selective, high-affinity synaptic vesicle protein 2A ligand and analog of levetiracetam indicated for the treatment of partial-onset seizures in patients with epilepsy.
Development timeline for Briviact
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.